ABSI Latest Headlines

Absci lines up three investor fireside chats across Boston, London, and Coral Gables

Market Chameleon (Tue, 27-Oct 8:09 AM)

ABSI Spotlight: Interim Phase 1 Signals Put Absci’s ABS-201 Hair-Loss Program on a 2H 2026 Proof-of-Concept Clock

Market Chameleon (Thu, 22-Oct 7:08 AM)

Absci’s AI Antibody Push Meets a New Bottleneck: Immune-Risk Screening Is Finally Scaling

Market Chameleon (Wed, 21-Oct 11:17 AM)

Absci highlights an estimated 65-day-plus half-life for ABS-201 as AI-designed biologics shift from design to lab proof

Market Chameleon (Thu, 15-Oct 8:53 AM)

Absci Sets November 12 Call for Q3 2026 Results, Spotlighting Its Generative AI Drug-Creation Platform

Market Chameleon (Tue, 13-Oct 9:32 AM)

Absci outlines a ~150-patient, 10+ country Phase 2 plan for ABS-201 in endometriosis, targeting mid-2027 initiation

Market Chameleon (Thu, 24-Sep 8:16 AM)

Function-Focused AI and Integrated Labs Set Absci Apart in Next-Gen Drug Discovery

Market Chameleon (Wed, 19-Aug 9:16 AM)